Smoking affects the interferon beta treatment response in multiple sclerosis

Objective To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)–DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A. Methods DNA from 834 IFN-β–treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire. Results We found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021–1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056–1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant. Conclusion In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.

[1]  P. Sørensen,et al.  The Danish Multiple Sclerosis Treatment Register , 2016, Clinical epidemiology.

[2]  H. Ullum,et al.  Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population. , 2016, Multiple sclerosis and related disorders.

[3]  T. Holmøy,et al.  No association of tobacco use and disease activity in multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[4]  P. Sørensen,et al.  Association between age at onset of multiple sclerosis and vitamin D level–related factors , 2016, Neurology.

[5]  David H. Miller,et al.  No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT , 2015, Neurology.

[6]  M. Bottai,et al.  Effect of Smoking Cessation on Multiple Sclerosis Prognosis. , 2015, JAMA neurology.

[7]  Calliope A. Dendrou,et al.  Class II HLA interactions modulate genetic risk for multiple sclerosis , 2015, Nature Genetics.

[8]  N. Koch-Henriksen,et al.  Prediction of response to interferon therapy in multiple sclerosis , 2014, Acta neurologica Scandinavica.

[9]  T. Olsson,et al.  Smoking and Risk of Multiple Sclerosis: Evidence of Modification by NAT1 Variants , 2014, Epidemiology.

[10]  T. Olsson,et al.  Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a , 2014, Multiple sclerosis.

[11]  C. Marck,et al.  The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis , 2014, Journal of the Neurological Sciences.

[12]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[13]  G. Hallmans,et al.  Smoking as a risk factor for multiple sclerosis , 2013, Multiple sclerosis.

[14]  C. Tench,et al.  Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study , 2013, Brain : a journal of neurology.

[15]  T. Åkerstedt,et al.  Shift work at young age is associated with increased risk for multiple sclerosis , 2011, Annals of neurology.

[16]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[17]  T. Olsson,et al.  Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. , 2011, Brain : a journal of neurology.

[18]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[19]  A. Ascherio,et al.  Epstein–Barr Virus Infection and Multiple Sclerosis: A Review , 2010, Journal of Neuroimmune Pharmacology.

[20]  T. Olsson,et al.  Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis , 2009, Neurology.

[21]  Eman N. Ali,et al.  Smoking and disease progression in multiple sclerosis. , 2009, Archives of neurology.

[22]  T. Dwyer,et al.  Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis , 2009, Journal of Neurology.

[23]  A. Lutterotti,et al.  Smoking is a risk factor for early conversion to clinically definite multiple sclerosis , 2008, Multiple sclerosis.

[24]  L. Nyström,et al.  Smoking worsens the prognosis in multiple sclerosis , 2008, Multiple sclerosis.

[25]  L. Nyström,et al.  Smoke exposure increases the risk for multiple sclerosis , 2008, European journal of neurology.

[26]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[27]  H. J. Hansen,et al.  Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey , 2006, Multiple sclerosis.

[28]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[29]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[30]  M. Hernán,et al.  Cigarette smoking and the progression of multiple sclerosis. , 2005, Brain : a journal of neurology.

[31]  P. Sørensen,et al.  Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.

[32]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[33]  G. Forster,et al.  Steroid Correlates of Territorial Behavior in Male Jacky Dragons, Amphibolurus muricatus , 2003, Brain, Behavior and Evolution.

[34]  M. Hernán,et al.  Cigarette smoking and incidence of multiple sclerosis. , 2001, American journal of epidemiology.

[35]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[36]  M. Ranke,et al.  Energy Expenditure, Energy Intake and Prevalence of Obesity after Therapy for Acute Lymphoblastic Leukemia during Childhood , 2000, Hormone Research in Paediatrics.

[37]  N. Koch-Henriksen,et al.  The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis , 2000, Multiple sclerosis.

[38]  F. Heidenreich,et al.  Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS , 2000, Neurology.

[39]  M. Dikshit,et al.  Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain , 1996, Experientia.

[40]  M. Vessey,et al.  Oral contraceptives and reproductive factors in multiple sclerosis incidence. , 1993, Contraception.

[41]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[42]  J. Hallpike.  New treatments for multiple sclerosis. , 1980, British journal of hospital medicine.